Research / Scientific departments / Structural Biology and Chemistry / Units and Groups / Pharmacology of Pain / Publications (2006-2012)

Publications (2006-2012)

Original and review articles
  1. Rosa, M., Arsequell, G., Rougeot, C., Calle, L., Marcelo, F. M., Pinto, M., Centeno, N. B., Jimenez-Barbero, J. and Valencia, G. (2012) A SAR study of opiorphin, a human dual ectopeptidase inhibitor with antinociceptive properties. J Med Chem. 55(3): 1181-1188.
  2. Tòth, F., Tòth, G., Benyhe, S., Rougeot, C. and Wollemann, M. (2012) Opiorphin highly improves the specific binding and affinity of MERF and MEGY to rat brain opioid receptors. Regulatory Peptides 178: 71-75.
  3. Pinto, M., Rougeot, C., Gracia, L., Rosa, M., Garcia, A., Arsequell, G., Valencia, G. and Centeno, N. B. (2011) Proposed Bioactive Conformations of Opiorphin, an Endogenous Dual APN/NEP Inhibitor. ACS Med. Chem. Lett. (J. Med. Chem.) 3, 20-24.
  4. Javelot, H., Weiner, L., Terramorsi, R., Rougeot, C., Lalonde, R. and Messaoudi, M. (2011) Efficacy of chronic antidepressant treatments in a new model of extreme anxiety in rats. Depres. Res. Treat. 2011: 531435.
  5. Messaoudi, M., Violle, N., Bisson, J. F., Desor, D., Javelot, H. and Rougeot C. (2011) Beneficial psychological effects of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in healthy human volunteers. Gut Microbes 2(4): 256-261
  6. Calenda, G., Tong, Y., Kanika, N. D., Tar, M. T., Suadicani, S. O., Xhang, X., Melman, A., Rougeot, C. and Davies, K. P. (2011) Reversal of Diabetic Vasculopathy in a Rat Model of Type 1 Diabetes by Opiorphin-Related Peptides. Am J Physiol Heart Circ Physiol. 301: H1353 - H1359.
  7. Seebach, D., Lukaszuk, A., Patora-Komisarska, K., Podwysocka, D., Gardiner, J., Ebert, M. O., Reubi, J. C., Cescato, R., Waser, B., Gmeiner, P., Hubner, H. and Rougeot, C. (2011) On the terminal homologation of physiologically active peptides as a means of increasing stability in human serum--neurotensin, opiorphin, B27-KK10 epitope, NPY. Chem Biodivers. 8, 711-739.
  8. Rougeot C., Robert F., Menz L., Bisson J.F. and Messaoudi M. (2010) Systemically active human Opiorphin is a potent yet non-addictive analgesic without drug tolerance effects. J. Physiol.  Pharmacol.. 61, 483-490.
  9. Rougeot C. (2010) La Sialorphine de rat et de l’Opiorphine humaine – deux nouveaux modulateurs physiologiques des voies opioïdergiques – J. AAEIP, 52,  44-47.
  10. Javelot H., Messaoudi M., Garnier S. and Rougeot C. (2010) Human Opiorphin is a naturally occurring antidepressant acting selectively on enkephalin-dependent delta-opioid pathways. J. Physiol.  Pharmacol., 61, 355-362.
  11. Rougeot C. and Messaoudi M. (2008) The Discovery of Rat Sialorphin and Human Opiorphin: new modulators of opioid-dependent pathways. Proceedings of the 4th International Peptide Symposium.  Jackie Wilce (Editor) on behalf of the Australian Peptide Society, 1-3.
  12. Hammoudi-Triki D., Lefort J., Rougeot, C., Robbe-Vincent A., Bon C., Laraba-Djebari F. and Choumet V. (2007) Pharmacokinetic and pharmacodynamic analyses of Androctonus australis hector venom in rats: Optimization of antivenom therapy. Toxicol.  Appl. Pharmacol., 218, 205-214.
  13. Davies K.P., Tar M., Rougeot C. and Melman A. (2007) Sialorphin (The Mature Peptide Product of Vcsa1) Relaxes Corporal Smooth Muscle Tissue and Increases Erectile Function in the Aging Rat. British J. of Urol. Int. Feb., 99, 431-435.
  14. Rougeot C. and Messaoudi M. (2007) Identification of human Opiorphin, a natural anti-nociceptive modulator of opioïd-dependent pathways. Med Sci. (Paris), 23, 33-35.
  15. Medja F., Fontaine R.H., Lebas F., Leroux P., Saria A., Rougeot C., Dournaud P., Lelièvre V. and Gressens P. (2006) Thiorphan, a neutral endopeptidase (NEP) inhibitor used for diarrhea, is neuroprotective in newborn mice. Brain, 129, 3209-3223.
  16. Wisner A., Dufour E., Messaoudi M., Nejdi A., Marcel A., Ungeheuer M.N. and Rougeot C. (2006) Human Opiorphin, a Natural Anti-nociceptive Modulator of Opioid-Dependent Pathways; Proc. Natl. Acad. Sci. USA, 103, 17979-17984.

Patents

• ROUGEOT C. Opiorphin as a biomarker –
  International application : PCT/EP2009/066002 deposited on 27-11-2009
• ROUGEOT C. Method for identifying Opiorphin agonists or antagonists
  International application : PCT/EP2009/050567 edited on 23-07-2009 N° WO/2009/090265
• ROUGEOT C. Opiorphin peptide derivatives as potent inhibitors of enkephalin-degrading ectopeptidases    
  International application : PCT/EP2009/054171 edited on 15-10-2009 N° WO/2009/124948.
• ROUGEOT C. Opiorphin for use as psychotimulant agent
  International application : PCT/EP2009/056390 edited on 17-12-2009 N° WO/2009/150040
• ROUGEOT C. et al. Peptides derived from human BPLP protein, polynucleotides coding for said peptides and
  antibodies directed against said peptides.
  International application PCT/IB2005/000700 edited on 29/09/2005, N° WO/2005/090386 and published on
  2006 in AU, EP and on 2008 in US.


Newspapers Articles – Movies

• 2006. La découverte d’une molécule anti-douleur naturelle: une aventure de recherche à l’Institut Pasteur – Vidéo 14 min : http://canal-educatif.fr/sciences_pasteur_6.htm
• 2006. Aussi efficace que la morphine chez le rat ; un puissant analgésique endogène identifié chez l’homme - Le quotidien du médecin n° 8050, p : 7
• 2007. L’Opiorphine futur traitement de la douleur – Pasteur le Mag (Mag2), p :24
• 2008. Un anti-douleur naturel – Le Pellerin n°6564, p :38
• 2010. Catherine Rougeot: l’Opiorphine, Video par SupBiotech: http://www.dailymotion.com/video/k3L2elP8rgEsIR1uq4H

• Autre: http://www.google.fr/search?q=opiorphin